Cambridge Cognition PLC, a neuroscience technology company, has formed a strategic partnership with ActiGraph to accelerate the adoption of digital measurements in central nervous system trials.
By joining ActiGraph’s Accelerant partnership programme, Cambridge Cognition aims to simplify access to raw data streams for digital health technologies in clinical development. This collaboration will enhance assessment capabilities in areas such as schizophrenia and dementia, addressing significant unmet needs.
Christine Guo, chief scientific officer at ActiGraph, highlighted the importance of objective data collection in CNS disorders, which can be prone to subjective biases. The partnership with Cambridge Cognition aims to provide advanced clinical insights for CNS trials by leveraging their expertise in digital data collection.
Cambridge Cognition specializes in touch-screen and voice-based digital assessments for cognition and brain health indicators. Their e-clinical technology solutions, which can be used in-clinic or remotely, offer flexibility in capturing critical clinical measures for pharmaceutical companies and research institutions.
Francesca Cormack, chief scientist at Cambridge Cognition, emphasized the need for objective digital measures in CNS disorders to accelerate treatment development and improve clinical trial efficiency. Together, Cambridge Cognition and ActiGraph aim to create more accurate multi-modal digital biomarkers by combining actigraphy data with brain health assessments.
